Levetiracetam Ucb (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in regulating neurotransmitter release. This binding modulates vesicle exocytosis, leading to reduced neuronal excitability and suppression of abnormal electrical activity that underlies seizure generation.

The dosing regimen for Levetiracetam Ucb is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The healthcare professional determines the appropriate infusion rate and total daily dose, which may be adjusted during therapy to achieve optimal seizure control while minimizing adverse effects.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainties with the patient and consider alternative therapies if appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levetiracetam Ucb. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Compared with many traditional antiepileptics, levetiracetam has a distinct mechanism targeting SV2A and generally exhibits fewer drug‑enzyme interactions. It is often preferred for patients who require rapid intravenous administration or who have experienced adverse effects with enzyme‑inducing agents such as carbamazepine or phenytoin. However, individual response and tolerability vary, so selection should be individualized.

Levetiracetam Ucb must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken vigorously. If the product reaches room temperature, it should be used promptly and not re‑refrigerated.

The medication is supplied as a sterile injectable solution for intravenous infusion. It is typically administered by a qualified healthcare professional through a controlled IV line, with the infusion rate and total daily dose determined by the prescribing clinician. Compatibility with common IV fluids should be confirmed before administration.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome, significant mood alterations like depression or suicidal thoughts, and hematologic abnormalities such as neutropenia or thrombocytopenia. Prompt medical attention is required if any of these events occur.

Levetiracetam Ucb is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for individuals with severe renal impairment who have not undergone dose adjustment, and for those with a history of serious psychiatric disorders without close monitoring.